Moore Capital Management, LP Adaptive Biotechnologies Corp Transaction History

Moore Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.5 - $12.67 $787,163 - $1.53 Million	121,102 Added 490.49%	145,792 $1.04 Million
Q2 2022 Aug 15, 2022	SELL	$6.4 - $14.73 $183,545 - $422,441	-28,679 Reduced 53.74%	24,690 $200,000
Q1 2022 May 16, 2022	SELL	$10.12 - $28.9 $1.04 Million - $2.98 Million	-103,242 Reduced 65.92%	53,369 $741,000
Q4 2021 Feb 14, 2022	BUY	$25.17 - $36.85 $1.37 Million - $2 Million	54,289 Added 53.06%	156,611 $4.4 Million
Q3 2021 Nov 15, 2021	BUY	$30.02 - $39.87 $639,786 - $849,709	21,312 Added 26.31%	102,322 $3.48 Million
Q2 2021 Aug 16, 2021	BUY	$32.22 - $44.59 $1.75 Million - $2.43 Million	54,401 Added 204.45%	81,010 $3.31 Million
Q1 2021 May 17, 2021	SELL	$37.26 - $67.74 $3.01 Million - $5.47 Million	-80,770 Reduced 75.22%	26,609 $1.07 Million
Q4 2020 Feb 16, 2021	BUY	$45.01 - $65.47 $4.83 Million - $7.03 Million	107,379 New	107,379 $6.35 Million

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.